What Long-Term Real-World Data on CAR T in Myeloma Could Reveal

Doris K. Hansen, MD, of Moffitt Cancer Center, contrasts real-world expectations for ciltacabtagene autoleucel (Carvykti; cilta-cel) against the historic benchmark data established by the CARTITUDE-1 clinical trial (NCT03548207). Long-term follow-up from CARTITUDE-1 revealed that an impressive 33% of heavily pretreated patients with relapsed or refractory multiple myeloma remain in remission and entirely treatment-free at the 5-year mark. Prior to the advent of modern chimeric antigen receptor (CAR) T-cell therapies, such durable, late-line survival outcomes were virtually unprecedented in clinical oncology.

A primary objective for current real-world patient cohorts is to replicate this substantial quantity of treatment-free time over extended tracking periods. Navigating a cellular therapy regimen demands an intensive upfront investment from patients, who must undergo a complex gauntlet of clinical appointments, invasive testing, and specialized monitoring. Hansen emphasizes that securing a prolonged, treatment-free remission window is paramount, as it directly justifies this treatment burden by simultaneously extending a patient’s quantity of life and maximizing their overall quality of life.

In addition to durable efficacy, maintaining a stable longitudinal safety and tolerability profile remains a key clinical focus. Investigators want to ensure that cumulative safety events and treatment-related mortality rates do not escalate as cohorts mature over time. A critical area of focus involves reducing the incidence of delayed, non-immune effector cell-associated neurotoxicity syndrome–neurologic toxicities (NINTs).

Hansen notes that CAR T specialists are becoming better equipped to predict, identify, and mitigate these severe neurological complications. Preventative advancements include optimizing patient bridging therapies prior to CAR T infusion and tracking early hematologic biomarkers, such as absolute lymphocyte count. Utilizing these predictive tools allows clinicians to intervene much earlier in the treatment course, safely preventing potentially fatal toxicities while preserving the drug’s profound antitumor activity.